Patient Enrollment Is Open for Phase 3 Study Evaluating HyBryte in CTCL
Patient enrollment is open for a confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL). HyBryte is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by […]